PARIS (dpa-AFX) - Acorda Therapeutics Inc. (ACOR) has decided to discontinue
the development of Dalfampridine for treatment of post-stroke walking
difficulties, following disappointing results from its trial, dubbed MILESTONE.
Although the study...
PARIS (dpa-AFX) - Sanofi announced that the U.S. Food and Drug
Administration approved once-daily Soliqua 100/33 (insulin glargine &
lixisenatide injection) 100 Units/mL & 33 mcg/mL for the treatment of adults
with type 2 diabetes inadequately...
The Foreign Investment Promotion Board will take up 11 proposals today, including those of Sanofi Synthelabo lndia and Gland Pharma. Other investment proposals on the table include those of Flag Tel...
Oops! Unable to complete your request. Please refresh your browser.